Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Dec 14, 2014; 20(46): 17498-17506
Published online Dec 14, 2014. doi: 10.3748/wjg.v20.i46.17498
Published online Dec 14, 2014. doi: 10.3748/wjg.v20.i46.17498
Genomic landscape of pancreatic neuroendocrine tumors
Niklas Gebauer, Christian Schmidt-Werthern, Veronica Bernard, Alfred C Feller, Christoph Thorns, Department of Pathology, University Hospital of Schleswig-Holstein, 23538 Luebeck, Germany
Tobias Keck, Nehara Begum, Department of Surgery, University Hospital of Schleswig-Holstein, 23538 Luebeck, Germany
Dirk Rades, Department of Radiation Oncology University Hospital of Schleswig-Holstein, 23538 Luebeck, Germany
Hendrik Lehnert, Georg Brabant, Department of Internal Medicine I, University Hospital of Schleswig-Holstein, 23538 Luebeck, Germany
Author contributions: Gebauer N and Schmidt-Werthern C contributed equally to this manuscript; Gebauer N performed molecular investigations, analyzed the data and wrote the manuscript; Schmidt-Werthern C and Bernard V performed molecular investigations and revised the manuscript; Feller AC revised the manuscript; Keck T, Begum N, Rades D, Lehnert H and Brabant G provided clinical data, assisted in data analysis and revised the manuscript; Thorns C designed the research, analyzed the data and revised the manuscript.
Supported by Thorns C and Brabant G received research funding from IPSEN Pharma GmbH (Ettlingen), Germany and Novartis Pharma GmbH, Nürnberg, Germany
Correspondence to: Niklas Gebauer, MD, Department of Pathology, University Hospital of Schleswig-Holstein, Campus Lübeck, Ratzenburger Allee 160, 23538 Luebeck, Germany. niklas.gebauer@medizin.uni-luebeck.de
Telephone: +49-451-5006011 Fax: +49-451-5006013
Received: March 29, 2014
Revised: May 3, 2014
Accepted: July 24, 2014
Published online: December 14, 2014
Revised: May 3, 2014
Accepted: July 24, 2014
Published online: December 14, 2014
Core Tip
Core tip: In the current study, we characterized the genomic landscape of pancreatic neuroendocrine tumors (PanNETs). Analysis of recurrent genomic amplifications delineated two independent clusters of genomic aberrations as well as two patient groups characterized by significantly overlapping cytogenetic features. Copy number alterations affecting chromosomes 6, 8, 9 and 17 were shown to be associated with survival. A high degree of genomic heterogeneity between primary tumor samples and metastatic lesions demonstrates the need for a more focused molecular and cytogenetic characterization in the light of upcoming targeted therapy approaches. PanNETs appear to be genetically distinct from other types of neuroendocrine tumors.